How much revenue does Amarantus BioScience make?

Amarantus BioScience reported $0 in revenue for fiscal year 2015. In Q1 2018 revenue was $0.

What companies are similar to Amarantus BioScience?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Pathfinder Cell Therapy, Inc. (PFND), Xeno Transplants Corporation (XENO), U.s. Stem Cell, Inc. (USRM), ReNeuron Group plc (RNUGF).

Amarantus BioScience Holdings, Inc. (AMBS) Stock

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietar...

At a glance

Amarantus BioScience reported revenue of $0 for fiscal year 2015, and net income of -$37.06 million. In Q1 2018 (the quarter ended March 31, 2018) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2015.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.